ArticleCommunications medicine2026
hERG epitope mimic-decoy peptide corrects autoimmune-long QT syndrome in guinea pigs.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe most investigated form of autoimmune-long-QT-syndrome (LQTS) is caused by circulating anti-Ro/SSA(Sjögren's syndrome-related antigen-A)-52kD antibodies, which cross-react with a specific sequence of the human ether-à-go-go-related (hERG) potassium channel's pore region, reducing the rapid inward-rectifying potassium current (I
methodsMDP4 was designed using 3D-structure-based protein engineering and optimized via conformational search and energy minimization. QT-interval prolongation was induced in an established guinea pig model of autoimmune-associated LQTS via injection of Ro/SSA-52kD antigen over 15 days. Upon confirmation of QT-interval prolongation, MDP4 was administered, and electrocardiogram parameters were monitored for 30 days. I
resultsGuinea pigs immunized with Ro/SSA-52kD antigen exhibit QTc prolongation and hERG-cross-reactive anti-Ro/SSA-52kD serum antibodies. In vivo treatment with MDP4 reverses QTc prolongation. MDP4 in vitro treatment of guinea pig ventricular myocytes also reverses I
conclusionsTreatment with MDP4 results in recovery of both the QT-interval prolongation in vivo and I
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.